Key result
The Accumetrics Ultegra RPFA-ASA system identified an incidence of aspirin nonresponsiveness of 23% in a prospective, multicenter study of 422 patients.
Why the study?
Does the Ultegra RPFA-ASA system accurately detect aspirin nonresponsiveness compared to optical aggregometry?
Observational (n=422)
Yes
Does the Ultegra RPFA-ASA system accurately detect aspirin nonresponsiveness compared to optical aggregometry?
The Ultegra RPFA-ASA system is a precise point-of-care assay that correlates well with optical aggregometry for detecting aspirin resistance, which was found in 23% of patients.
No takes yet. Share an insight, caveat, or question.
Point-of-care aspirin testing detects nonresponsiveness; leaves open its clinical utility for guiding therapy.
Coleman et al. (2004) conducted an observational in Patients at risk for cardiovascular disease on aspirin therapy (n=422). Accumetrics Ultegra RPFA-ASA System was evaluated on Incidence of aspirin nonresponsiveness. The Accumetrics Ultegra RPFA-ASA system identified an incidence of aspirin nonresponsiveness of 23% in a prospective, multicenter study of 422 patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: